Page Limit Blunder Blocks Janssen’s Bid To Bar Amgen’s Ustekinumab
US District Court Pulls Up Janssen For Seven Minute Warning To Its Request
Executive Summary
Janssen was pulled up for paperwork chicanery as it looked to obtain an early preliminary injunction against Amgen’s proposed biosimilar to its Stelara (ustekinumab).